Moreover, inhibitors of BET binding can disrupt the growth of cancer cells and this phenomenon has been attributed to the sensitivity of super-enhancers, driving oncogenes such as MYC and BCL2, to BET disruption [26,27]. This evidence concerns the gene MYC and cancer.